Scilex Holding Company has 4 Schedule 13D or 13G filings on record since 2025-08-14. 1 holder's latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| SCLX Stock Acquisition JV LLC | 11.4% | 30,029,378 | SCHEDULE 13D/A, 2026-07-07 | 2026-07-03 |
| Oramed Pharmaceuticals Inc. | 4.9% | 437,510 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
Purpose of Transaction (Item 4)
SCLX Stock Acquisition JV LLC
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On April 15, 2025, the Issuer effected a reverse stock split of the Common Stock at a ratio of 1-for-35 (the "Reverse Stock Split"). The share information in this Amendment No. 6 reflects the effect of the Reverse Stock Split. On July 3, 2026, the Reporting Person entered into a letter agreement (the "Letter Agreement") with the Issuer and Quantum Scan Holdings, Inc. ("Q Scan"), pursuant to which the Reporting Person transferred 500,000 shares of Common Stock held by the Reporting Person to Q Scan in exchange for shares of common stock of Q Scan. The price at which such shares are being transferred to Q Scan will be based on the closing price of the shares of Issuer common stock on the Nasdaq Capital Market on the last trading day immediately prior to the transfer of such shares pursuant to the Letter Agreement.Item 4 of the SCHEDULE 13D/A filed 2026-07-07
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Oramed Pharmaceuticals Inc. | 9.9% | SCHEDULE 13G/A |
| 2025-11-14 | Oramed Pharmaceuticals Inc. | 9.9% | SCHEDULE 13G/A |
| 2026-02-13 | Oramed Pharmaceuticals Inc. | 4.9% | SCHEDULE 13G/A |
| 2026-07-07 | SCLX Stock Acquisition JV LLC | 11.4% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Scilex Holding Company. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.